HK Stock Market Move | OCUMENSION-B(01477) has surged nearly 7%. The new drug Zhiweitai, which treats allergic conjunctivitis, has been approved for domestic marketing.

OCUMENSION-B (01477) rose nearly 7%, as of the time of publication, it rose by 6.84%, closing at HK$4.84, with a trading volume of HK$2.3355 million. On the news front, Ocumension Bio yesterday announced that the application for registration of the market-approved anti-allergy and highly selective histamine H-1 receptor antagonist OT-1001 (Ziwetai) has recently been approved by the China National Medical Products Administration. It is reported that OT-1001 is the first and only eye drop formulation of the anti-histamine drug levocetirizine hydrochloride (active ingredient of ZYRTEC), which is currently marketed in the United States for the treatment of eye itching related to allergic conjunctivitis. As of now, the company has a total of 33 drug assets in the anterior and posterior segments of the eye, 20 products are in the commercialization stage, 3 products are in phase III clinical trials, 2 products have entered the commercialization registration stage, and the core product Ushiyin (0.18mg fluorometholone vitreous implant) has been approved and listed in China and included in national medical insurance. The innovative anti-allergy drug Ziwetai (levocetirizine hydrochloride eye drops) has also been approved and launched in China.